STOCKS TELEGRAPH

Tag: SNOA

  • Sonoma Pharmaceuticals Inc. (SNOA) stock Bullish on News of Partner Network Expansion

    On January 20, Sonoma Pharmaceuticals Inc. (SNOA) announced its partner network expansion for oral and dental products in the U.S. and China. Following the announcement, the stock became bullish in the after-hours session.

    The stock was gloomy in regular trading as it lost 2.30% at its closing price of $4.25 on Thursday. Consequent to the news, SNOA reversed to add 8.00% in the after-hours. Hence, it was trading a $4.59 per share at an after-hours volume of 259.52K shares.

    Sonoma Pharmaceuticals Inc. has a market capitalization of $13.47 million. Currently, the company has 3.1 million shares outstanding in the market.

    SNOA’s Partner Network Expansion

    Firstly, the company has expanded its U.S. dental care partner network by adding Salus Medical as a distribution partner. Furthermore, the company has entered into a non-exclusive agreement with Salus Medical for the distribution of Endocyn® root canal irrigant. Additionally, with SNOA’s Microcyn® RX and Regenacyn® Plus products, Salus Medical would widen its dermatology offerings. Salus Medical will have non-exclusive rights for the distribution of Microcyn® products.

    Salus Medical is a Phoenix, Arizona-based national wholesale distributor.

    Secondly, the company has also entered into a partnership deal with Anlicare International. Thus, Expanding its oral and dental care line to China. On January 18, SNOA and Anlicare agreed for working on the completion of required regulatory work for obtaining Microcyn®-based products distribution licenses in China. As per the agreement, Anlicare will be responsible for the regulatory costs. In return, the company will grant exclusive distribution rights to Anlicare for oral and dental care products in China.

    Anlicare International brings and commercializes innovative medical devices and consumables to the Chinese market.

    Recent Participation

    Recently, the company participated in the H.C. Wainwright BioConnect Virtual Healthcare Conference. The conference took place from January 10 to January 13, 2022. SMOA’s CEO, Amy Trombly, and CFO, Jerry Dvonch presented an overview of the company’s business at the conference.

    SMOA’s Q2 FY2022 Financials

    On November 15, the company announced its financial results for the second quarter of fiscal 2022, which ended on September 30, 2021.

    In the second fiscal quarter of 2022, the revenues were $3,744,000 against $5,769,000 in the year-ago quarter. Hence, showing a decrease of 35% year over year.

    Moreover, SMOA suffered a net loss of $95,000 from continuing operations in Q2 of fiscal 2022. Comparatively, the company had a net income of $151,000 in the same period last year.

  • Sonoma Pharmaceuticals, Inc. (SNOA) Stock Drops Significantly Despite Promising Financial Reports for Fiscal Q4 2021

    Sonoma Pharmaceuticals, Inc. (SNOA) stock prices were down 18.88% some time after market trading commenced on July 15th, 2021, bringing the price per share down to USD$6.23 early on in the trading day.

    Partnership with EMC Pharma

    March 26th, 2021 saw the company report having entered into a new partnership with EMC Pharma in light of it having gained exclusive rights for the U.S commercialization of prescription dermatology and prescription eye care products. The pharmaceutical company was also granted non-exclusive rights to sell their wound care products into government channels. The initial term of the agreement is subject to minimum purchases and is set for five years, with the option to renew.

    Network of Partnerships

    September 2020 saw the company launch two new products, Nasocyn Nasal Care and Oracyn Oral Care in collaboration with its partner, Te Arai Biofarma Ltd. December 2020 saw the company partner up with Gabriel Science, LLC in order to penetrate the dental markets in the U.S with their HOCI product. January 2021 saw the company receive clearances in Thailand, after which the sales of Dermodacyn disinfectant commenced in Hong Kong and Thailand, through its partner, VetSynova Co. Ltd.

    Total Revenues

    Total Revenues for the quarter ended March 31st, 2021 came in at USD$2.2 million, down by USD$2.1 million as compared to the same time period of the prior year. The 50% reduction was largely driven by the USD$1.6 million decline in the U.S, which, in turn, was motivated by the decline of the company’s dermatology business. The dermatology business has since been partnered with EMC Pharma, LLC. Further compounding the year-over-year difference was USD$800,000 in revenue adjustments in relation to the overestimation of revenue in the prior-year quarter, having been determined using a look-back analysis.

    Invekra Contract

    As a result of the Invekra contract having concluded in October of 2020 resulted in a USD$0.7 million reduction in revenues generated from Latin America sales, further contributing to the yearly difference in total revenue. As per the contract, SNOA the company manufactured at low margins for Invekra. Since the conclusion of the contract, manufacturing has continued at reduced quantities but higher margins.

    Future Outlook for SNOA

    Armed with a network of partnerships secured over the past few quarters, SNOA is poised to capitalize on the chances afforded to it. The company is keen to continue its trajectory of success as it pushes for the consolidation and expansion of its market footprint around the globe. Current and potential investors are hopeful that management will be able to usher in sustained and significant increases in shareholder value.

  • Sonoma Pharmaceuticals Inc. (SNOA) stock rises during pre-market trading. Here’s to know why?

    Sonoma Pharmaceuticals Inc. (SNOA) stock surged by 8.47% at the last trading close whereas the SNOA rises by 26.78% in the pre-market trading after it announced their agreement with EMC Pharma, LLC. Sonoma Pharmaceuticals is a worldwide healthcare pioneer in the development and production of stabilized hypochlorous acid (HOCl) products for wound treatment, animal health, eye care, nasal care, oral care, disinfectant use, and dermatological conditions.

    What is happening?

    Sonoma announced that it has entered into a definitive agreement with EMC Pharma, LLC for the exclusive right to manage, market, and distribute Sonoma’s HOCl-based prescription dermatology and eye care products in the United States for a five-year period, with an option to extend. EMC Pharma will also have a non-exclusive contract with the government to manage, supply, and distribute such Microcyn-based wound care products. EMC Pharma is a national healthcare products and services firm that operates in FDA-approved prescription medication creation, pharmaceutical distribution, and effective pharmacy services.

    EMC will purchase all of the current inventory and pay a royalty and transfer rates for the first five years as part of the collaboration deal. To keep the distribution rights reserved, the parties agreed on certain minimum purchase conditions. The CEO of SNOA said that, through this agreement with EMC we are intending to increase our distributor network in order to enhance their approach for patients and consumers on national level and for this purpose EMC is the most appropriate platform due to its wide distribution network and experience in this business.

    Furthermore,

    Sonoma’s direct sale model was not really working in favor of SNOA therefore following this new agreement SNOA has reduced its sales force, working for the direct sale model in USA. The management of SNOA hopes that partnering with EMC would enable the company to cut costs while working with EMC to develop a profitable distribution model for its prescription drugs.

    Hence, this recent development in SNOA has caught the attention of investors which resulted in the rise of SNOA stock price. But the investors are still expected to be more careful before they make bet for a long-term.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.

  • Pre-Market Cues: 30 Stocks Roaring for Change On December 14th

    Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter products.

    Livent Corporation (NYSE: LTHM) shares are trading up 3.6% at $17.0 at the time of writing. Company’s 52-week ranged between $3.95 to $17.53. Analysts have a consensus price target of $16.50.

    Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) shares are trading down -5.45% at $2.95 at the time of writing after declaring offering of common stock. Company’s 52-week ranged between $1.03 to $5.31.

    NextDecade Corporation (NEXT) is down more than -7.25% at $3.2 in pre-market hours Monday December 14, 2020. The stock had jumped over 38.00% to $3.45 in the last trading session.

    FAT Brands Inc. (FAT) tumbled over -4.06% at $7.57 in pre-market trading today following the announcement from the company that it has entered into an agreement to combine with Fog Cutter Capital Group Inc. (FCCG), the Company’s controlling stockholder.

    Recro Pharma Inc. (REPH) stock soared 3.21% to $3.05 in the pre-market trading. The most recent rating by Stephens, on October 17, 2019, is an Overweight.

    Ampio Pharmaceuticals Inc. (AMPE) stock moved up 3.33 percent to $1.55 in the pre-market trading.

    ReTo Eco-Solutions Inc. (RETO), a Building Materials company, rose about 3.91% at $0.665 in pre-market trading Monday.

    Yiren Digital Ltd. (YRD) lost over -5.36% at $3.0 in pre-market trading Monday December 14, 2020. The firm recently announced that it has entered into two collaborative research agreements to explore new clinical indications for its immunomodulatory drug, Ampion™.

    Before the trading started on December 14, 2020, Sabre Corporation (SABR) is up 3.46% to reach $11.35. It has been trading in a 52-week range of $3.30 to $23.25.

    NantHealth Inc. (NH) is up more than 1.74% at $3.5 in pre-market hours Monday December 14, 2020. The company recently presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars. The stock had jumped over 22.42% to $3.44 in the last trading session.

    Torchlight Energy Resources Inc. (TRCH) stock soared 15.79% to $0.88 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    NIO Limited (NYSE: NIO) shares are trading down -6.38% at $39.3 at the time of writing following the announcement of pricing of offering of 68,000,000 American Depositary Shares. Company’s 52-week ranged between $2.11 to $57.20. Analysts have a consensus price target of $59.

    Lightbridge Corporation (LTBR) is down more than -2.4% at $3.66 in pre-market hours Monday December 14, 2020. The stock had jumped over 12.28% to $3.75 in the last trading session.

    Foresight Autonomous Holdings Ltd. (FRSX) stock moved up 2.31 percent to $1.77 in the pre-market trading after its affiliate, Rail Vision Ltd., has received an order from Knorr-Bremse Systeme für Schienenfahrzeuge GmbH, an affiliate of Knorr-Bremse AG (Frankfurt: KBX), for two samples of their light rail vehicle (LRV) system.

    Before the trading started on December 14, 2020, Hennessy Capital Acquisition Corp. IV (HCAC) is up 2.32% to reach $20.75. It has been trading in a 52-week range of $9.21 to $22.43.

    Inseego Corp. (INSG) stock soared 10.36% to $15.18 in the pre-market trading after reporting that the company is expanding its global footprint in Japan with the launch of its industry-leading 5G MiFi® M2000 mobile hotspot. The most recent rating by ROTH Capital, on August 06, 2020, is a Neutral.

    Mechel PAO (MTL) is down more than -3.66% at $1.84 in pre-market hours Monday December 14, 2020. The stock had jumped over 11.05% to $1.91 in the last trading session.

    JinkoSolar Holding Co. Ltd. (NYSE: JKS) shares are trading up 3.58% at $54.9 at the time of writing after declaring an update to 2020 annual general meeting agenda. Company’s 52-week ranged between $11.42 to $90.20. Analysts have a consensus price target of $55.

    Before the trading started on December 14, 2020, CureVac N.V. (CVAC) is up 6.7% to reach $125.99. It has been trading in a 52-week range of $36.15 to $151.80.

    Xeris Pharmaceuticals Inc. (XERS) grew over 2.84% at $4.7 in pre-market trading today after recent proclamation from company that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive Opinion for Ogluo™ (glucagon).

    Teligent Inc. (NASDAQ: TLGT) shares are trading up 85.54% at $1.17 at the time of writing. Company’s 52-week ranged between $0.46 to $6.46. Analysts have a consensus price target of $2.

    Marathon Patent Group Inc. (MARA) gained over 15.58% at $5.49 in pre-market trading Monday December 14, 2020. The firm recently announced a contract with Bitmain to purchase 10,000 Antminer S-19j Pro ASIC Miners.

    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 4.64% at $0.53 at the time of writing after reporting that it has received approval to transfer the listing of its common shares to the Nasdaq Capital Market. Company’s 52-week ranged between $0.14 to $3.88.

    Neos Therapeutics Inc. (NEOS) tumbled over -5.61% at $0.6532 in pre-market trading today. The company and Aytu BioScience, Inc. (AYTU) recently declared that they have entered into a definitive merger agreement pursuant to which Neos will merge with a wholly owned subsidiary of Aytu in an all-stock transaction.

    Arbutus Biopharma Corporation (ABUS), a Biotechnology company, rose about 6.14% at $4.15 in pre-market trading Monday. The healthcare firm lately declared additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

    Greenwich LifeSciences Inc. (GLSI) lost over -16.07% at $47.0 in pre-market trading Monday December 14, 2020 following the publication of a second poster for the GP2 Phase III clinical trial design for recurring breast cancer at the San Antonio Breast Cancer Symposium (SABCS) in a virtual format.

    Veru Inc. (VERU) is up more than 19.12% at $7.57 in pre-market hours Monday December 14, 2020 following the company revealed positive Phase 2 clinical trial results for enobosarm, for the treatment of endocrine and chemotherapy resistant ER+/HER2- metastatic breast cancer. The stock had jumped over 6.45% to $6.36 in the last trading session.

    NanoVibronix Inc. (NAOV) stock plunged -6.36% to $1.03 in the pre-market trading after reporting that it has expanded and replaced its original distribution agreement with Ultra Pain Products, Inc..

    SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares are trading down -11.23% at $7.43 at the time of writing following the pricing of $16.2 million registered direct offering. Company’s 52-week ranged between $1.46 to $19.38.

  • Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares taking aerial root after this announcement

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) shares hiked 32.30%  to reach $8.11 in the pre-market session after the announcement that they have reached a license and supply agreement for exclusive rights to market and sell products in the United States for over-the-counter (OTC) dermatological products.

    Crown plans to sell Sonoma’s Microcyn technology dermal sprays and gels targeting itch and pain under Sarna, the #1 Dermatologist Recommended Anti-Itch Brand, with a unique variety of formulations to quickly relieve itch and skin irritations.

    The HOCl line of products from Sonoma is clinically proven to reduce burning, itching, and pain in patients suffering from different kinds of dermatoses, including radiation dermatitis and atopic dermatitis. Sonoma will continue to sell prescription drugs, while Crown will offer over-the-counter products.

  • Sonoma Pharmaceuticals (SNOA) announced its financial results for the 2nd quarter and 6 months

    Sonoma Pharmaceuticals (SNOA) announced its financial results for the 2nd quarter and 6 months

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a multinational healthcare giant, has released financial results for its second fiscal quarter and six months ended September 30, 2020, manufacturing and supplying stabilized hypochlorous acid (HOCl) drugs for a wide variety of uses, including wound treatment, eye care, nasal care, oral care, and dermatological disorders. It also announced that, because of factual irregularities, it had to restate its first-quarter financial statements for the quarter ended June 30, 2020. The key highlights for the 6 months, ended September 30, 2020

    Sonoma recently completed the transition from Petaluma, CA to Woodstock, GA during the second fiscal year All manufacturing is now achieved at the state-of-the-art Sonoma plant in Zapopan, Mexico. As a result of this reorganization, Sonoma plans to see a continuous decrease in both overhead and the cost of products sold.

    Joint research was conducted in the Journal of Hospital Infection by the University of Hong Kong and Queen Mary Hospital using Dermodacyn Disinfecting solution, a medical-grade solution manufactured by Sonoma and marketed in Hong Kong by Sonoma partner Microderm Technologies Limited.   The study found that Dermodacyn Disinfecting solution significantly decreased the viability of SARS-CoV-2 against other laboratory and domestic disinfectants that are widely used.

    As the company works with its multinational network of retail partners to increase the number of goods and markets where such products are sold, Sonoma’s international market has continued to demonstrate strength. Sonoma, for instance, partnered with its affiliate Te Arai BioFarma to launch two new nasal and oral care brands in Australia and New Zealand, as previously announced on September 9, 2020.

    With an average rise in sales and a decline in operational expenses, Sonoma’s operating efficiency tends to grow quarter after quarter. Although the COVID-19 pandemic has created a daunting global climate, the versatility of Sonoma’s product lines and global markets served has not only proved to separate Sonoma from geographical downturns, but in some countries, the company’s anti-viral and anti-bacterial drugs have seen elevated demand.

  • Top Stocks As Federal Reserve Restores Market Confidence

    Top Stocks As Federal Reserve Restores Market Confidence

    The equity markets have regained upside momentum this afternoon. This follows the Fed’s decision to keep supporting the markets.  A statement from the FOMC said that the direction the economy takes will depend heavily on the coronavirus and that the virus will significantly affect employment numbers and inflation. The Fed then added that it was ready to use a wide array of tools to support the economy.

    The Federal Reserve further stated that it would increase its levels of treasury securities, and both commercial and residential mortgage-backed securities at current prices.  The news has seen the major stock indices rally with the NASDAQ now up by 1.50%. Individual stocks are also on the rise. The most visible stock gainer today is Kodak, which is up by 500%, dwarfing the stellar day that it had in yesterday’s trading session. Besides Kodak, other stocks that have recorded significant gains this afternoon are as below:

    Tupperware Brands Corporation [NYSE:TUP]

    This is one of the biggest gainers in the day and is up by 62% this afternoon.  The rally follows the company’s strong Q2 results that have beat analyst expectations. The company announced that its diluted EPS was 60% higher than the amount that it reported in 2019.

    The company also announced that in the quarter, its cash flow from its operations was higher by $71 million compared to Q2 of 2019. Nonetheless, the company reported that due to the COVID-19 pandemic, sales declined by 16% compared to the previous quarter.  CEO Sandra Harris noted that the increase in profitability was due to the company’s commitment to improve its profit margins and strengthen the balance sheet.

    Sonoma Pharmaceuticals Inc [NASDAQ:SNOA]

    Sonoma Pharmaceuticals Inc is another top performer this afternoon and is up by 52%. These gains come just a day after the company announced that Microsafe® disinfectant had passed the compatibility test for Boeing and Airbus commercial planes. The company’s CEO Amy Trombly stated that they were happy with the tests and that they expanded the company’s potential sales in the airline market, due to the COVID-19 pandemic. She added that the company was continually looking to grow its market reach across the globe.

    Big 5 Sporting Goods Corporation [NASDAQ:BGFV]

    This is another top gainer this afternoon and is up by 49%.  Its gains come after it reported impressive Q2 results. The company announced that its net income for Q2 stood at $11.1 million and that it was reinstating dividends. It further announced that store sales shot up by 31% and that it now had a cash position of around $38 million.